Manejo clí­nico y terapéutico en pacientes con cirrosis hepótica

Autores/as

DOI:

https://doi.org/10.23857/dc.v7i4.2412

Palabras clave:

Sepsis grave, Insuficiencia renal, Encefalopatía hepática, Hemorragia variceal, Fracaso hepático agudo sobre crónico, Pronóstico.

Resumen

Los pacientes cirróticos presentan frecuentemente complicaciones graves de su enfermedad que requieren ingreso en la UCI. La encefalopatí­a hepótica gradoIII-IV, el shock séptico, el fracaso agudo sobre crónico y la hemorragia variceal son descompensaciones que precisan un tratamiento intensivo especí­fico en el paciente cirrótico. La mayor eficacia de los tratamientos empleados en cuidados intensivos y la generalización de los programas de trasplante hepótico han mejorado de manera sustancial el pronóstico del paciente cirrótico crí­tico, hecho que ha facilitado su ingreso en las unidades de terapia intensiva. Sin embargo, el conocimiento de digestólogos e intensivistas sobre la patogenia, diagnóstico y tratamiento de estas complicaciones y sobre la evaluación pronóstica del paciente cirrótico crí­tico es limitado. Las alteraciones hemodinómicas y en la coagulación caracterí­sticas de estos pacientes y la disfunción inmune que presentan aumentan la complejidad del tratamiento, el riesgo de presentar nuevas complicaciones y su mortalidad en comparación con la población general.

Biografía del autor/a

José Raúl Bravo-Coello, Investigador Independiente.

Médico, Investigador Independiente.

Vanessa Adriana Pacheco-Moreira, Investigador Independiente.

Médico, Investigador Independiente.

Maribel Carolina Monar-Goyes, Investigador Independiente.

Médico, Investigador Independiente.

Jhuleydi Cumanda Chuncho-Romero, Investigador Independiente.

Médico, Investigador Independiente.

Citas

T. Gustot, F. Durand, D. Lebrec, J.L. Vincent, R. Moreau.Severe sepsis in cirrhosis.Hepatology, 50 (2009), pp. 2022-2033http://dx.doi.org/10.1002/hep.23264 | Medline

J. Fernandez, T. Gustot.Management of bacterial infections in cirrhosis.J Hepatol, 56 (2012), pp. S1-S12http://dx.doi.org/10.1016/S0168-8278(12)60002-6 | Medline

M.G. Foreman, D.M. Mannino, M. Moss.Cirrhosis as a risk factor for sepsis and death: Analysis of the National Hospital Discharge Survey.Chest, 124 (2003), pp. 1016-1020Medline

R. Jalan, J. Fernández, R. Wiest, B. Schnabl, R. Moreau, P. Angeli, et al.Bacterial infections in cirrhosis: A position statement based on the EASL Special Conference 2013.J Hepatol, 60 (2014), pp. 1310-1324http://dx.doi.org/10.1016/j.jhep.2014.01.024 | Medline

T. Gustot, P. Felleiter, P. Pickkers, Y. Sakr, J. Rello, D. Velissaris, et al.Impact of infection on the prognosis of critically ill cirrhotic patients: Results from a large worldwide study.Liver Int, 34 (2014), pp. 1496-1503http://dx.doi.org/10.1111/liv.12520 | Medline

R.P. Dellinger, M.M. Levy, A. Rhodes, D. Annane, H. Gerlach, S.M. Opal, et al.Surviving sepsis campaign: International guidelines for management of severe sepsis and septic shock: 2012.Crit Care Med, 41 (2013), pp. 580-637http://dx.doi.org/10.1097/CCM.0b013e31827e83af | Medline

D.M. Yealy, J.A. Kellum, D.T. Huang, A.E. Barnato, L.A. Weissfeld, F. Pike, ProCESS Investigators, et al.A randomized trial of protocol-based care for early septic shock.N Engl J Med, 370 (2014), pp. 1683-1693http://dx.doi.org/10.1056/NEJMoa1401602 | Medline

S.L. Peake, A. Delaney, M. Bailey, R. Bellomo, P.A. Cameron, D.J. Cooper, ARISE Investigators, ANZICS Clinical Trials Group, et al.Goal-directed resuscitation for patients with early septic shock.N Engl J Med, 371 (2014), pp. 1496-1506http://dx.doi.org/10.1056/NEJMoa1404380 | Medline

R. Moreau, S.S. Lee, T. Soupison, J. Roche-Sicot, C. Sicot.Abnormal tissue oxygenation in patients with cirrhosis and liver failure.J Hepatol, 7 (1988), pp. 98-105Medline

P. Gines, J. Fernandez, F. Durand, F. Saliba.Management of critically-ill cirrhotic patients.J Hepatol, 56 (2012), pp. S13-S24http://dx.doi.org/10.1016/S0168-8278(12)60003-8 | Medline

A. Kumar, D. Roberts, K.E. Wood, B. Light, J.E. Parrillo, S. Sharma, et al.Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock.Crit Care Med, 34 (2006), pp. 1589-1596http://dx.doi.org/10.1097/01.CCM.0000217961.75225.E9 | Medline

Y.M. Arabi, S.I. Dara, Z. Memish, A. al-Abdulkareem, H.M. Tamim, N. al-Shirawi, et al.Antimicrobial therapeutic determinants of outcomes from septic shock among patients with cirrosis.Hepatology, 56 (2012), pp. 2305-2315http://dx.doi.org/10.1002/hep.25931 | Medline

A. Perner, N. Haase, A.B. Guttormsen, J. Tenhunen, G. Klemenzson, A. í…neman, et al.Hydroxyethyl starch 130/0.42 versus Ringer's acetate in severe sepsis.N Engl J Med, 367 (2012), pp. 124-134http://dx.doi.org/10.1056/NEJMoa1204242 | Medline

R. Zarychanski, A.M. Abou-Setta, A.F. Turgeon, B.L. Houston, L. McIntyre, J.C. Marshall, et al.Association of hydroxyethyl starch administration with mortality and acute kidney injury in critically ill patients requiring volume resuscitation: A systematic review and meta-analysis.JAMA, 309 (2013), pp. 678-688http://dx.doi.org/10.1001/jama.2013.430 | Medline

P. Caironi, G. Tognoni, S. Masson, R. Fumagalli, A. Pesenti, M. Romero, et al.Albumin replacement in patients with severe sepsis or septic shock.N Engl J Med, 370 (2014), pp. 1412-1421http://dx.doi.org/10.1056/NEJMoa1305727 | Medline

P. Sort, M. Navasa, V. Arroyo, X. Aldeguer, R. Planas, L. Ruiz-del-Arbol, et al.Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis.N Engl J Med, 341 (1999), pp. 403-409http://dx.doi.org/10.1056/NEJM199908053410603 | Medline

J.A. Russell, K.R. Walley, J. Singer, A.C. Gordon, P.C. Hí©bert, D.J. Cooper, VASST Investigators, et al.Vasopressin versus norepinephrine infusion in patients with septic shock.N Engl J Med, 358 (2008), pp. 877-887http://dx.doi.org/10.1056/NEJMoa067373 | Medline

D. De Backer, P. Biston, J. Devriendt, C. Madl, D. Chochrad, C. Aldecoa, SOAP II Investigators, et al.Comparison of dopamine and norepinephrine in the treatment of shock.N Engl J Med, 362 (2010), pp. 779-789http://dx.doi.org/10.1056/NEJMoa0907118 | Medline

G. Fede, L. Spadaro, T. Tomaselli, G. Privitera, G. Germani, E. Tsochatzis, et al.Adrenocortical dysfunction in liver disease: A systematic review.Hepatology, 55 (2012), pp. 1282-1291http://dx.doi.org/10.1002/hep.25573 | Medline

M.H. Tsai, Y.S. Peng, Y.C. Chen, N.J. Liu, Y.P. Ho, J.T. Fang, et al.Adrenal insufficiency in patients with cirrhosis, severe sepsis and septic shock.Hepatology, 43 (2006), pp. 673-681http://dx.doi.org/10.1002/hep.21101 | Medline

J. Fernandez, A. Escorsell, M. Zabalza, V. Felipe, M. Navasa, A. Mas, et al.Adrenal insufficiency in patients with cirrhosis and septic shock: Effect of treatment with hydrocortisone on survival.Hepatology, 44 (2006), pp. 1288-1295

http://dx.doi.org/10.1002/hep.21352 | Medline

Y.M. Arabi, A. Aljumah, O. Dabbagh, H.M. Tamim, A.H. Rishu, A. Al-Abdulkareem, et al.Low-dose hydrocortisone in patients with cirrhosis and septic shock: A randomized controlled trial.CMAJ, 182 (2010), pp. 1971-1977http://dx.doi.org/10.1503/cmaj.090707 | Medline

E. Levesque, F. Saliba, P. Ichaí¯, D. Samuel.Outcome of patients with cirrhosis requiring mechanical ventilation in ICU.J Hepatol, 60 (2014), pp. 570-578http://dx.doi.org/10.1016/j.jhep.2013.11.012 | Medline

I. Khamaysi, N. William, A. Olga, I. Alex, M. Vladimir, D. Kamal, et al.Sub-clinical hepatic encephalopathy in cirrhotic patients is not aggravated by sedation with propofolcompared to midazolam: A randomized controlled study.J Hepatol, 54 (2011), pp. 72-77http://dx.doi.org/10.1016/j.jhep.2010.06.023 | Medline

P.M. Palevsky, J.H. Zhang, T.Z. O’Connor, G.M. Chertow, S.T. Crowley, D. Choudhury, VA/NIH Acute Renal Failure Trial Network, et al.Intensity of renal support in critically ill patients with acute kidney injury.N Engl J Med, 359 (2008), pp. 7-20http://dx.doi.org/10.1056/NEJMoa0802639 | Medline

S. Finfer, D.R. Chittock, S.Y. Su, D. Blair, D. Foster, V. Dhingra, NICE-SUGARStudy Investigators, et al.Intensive versus conventional glucose control in critically ill patients.N Engl J Med, 360 (2009), pp. 1283-1297http://dx.doi.org/10.1056/NEJMoa0810625 | Medline

R. De Franchis.Baveno VI Faculty. Expanding consensus in portal hypertension: Report of the Baveno VI Consensus Workshop: Stratifying risk and individualizing care for portal hypertension.J Hepatol, 63 (2015), pp. 743-752http://dx.doi.org/10.1016/j.jhep.2015.05.022 | Medline

P. Giní¨s, R.W. Shcrier.Renal failure in cirrhosis.New Engl J Med, 361 (2009), pp. 1279-1290http://dx.doi.org/10.1056/NEJMra0809139 | Medline

R.L. Mehta, J.A. Kellum, S.V. Shah, B.A. Molitoris, C. Ronco, D.G. Warnock, Acute Kidney Injury Network, et al.Acute Kidney Injury Network: Report as an initiative to improve outcomes in acute kidney injury.Crit Care, 11 (2007), pp. R31http://dx.doi.org/10.1186/cc5713 | Medline

C. Fagundes, R. Barreto, M. Guevara, E. Garcia, E. Solí , E. Rodriguez, et al.A modified acute kidney injury classification for diagnosis and risk stratification of impairment of kidney function in cirrhosis.J Hepatol, 59 (2013), pp. 474-481http://dx.doi.org/10.1016/j.jhep.2013.04.036 | Medline

S. Piano, S. Rosi, G. Maresio, S. Fasolato, M. Cavallin, A. Romano, et al.Evaluation of the Acute Kidney Injury Network criteria in hospitalized patients with cirrhosis and ascites.J Hepatol, 59 (2012), pp. 482-489http://dx.doi.org/10.1016/j.jhep.2013.03.039 | Medline

F. Salerno, A. Gerbes, P. Giní¨s, F. Wong, V. Arroyo.Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis.Gut, 56 (2007), pp. 1310-1318http://dx.doi.org/10.1136/gut.2006.107789 | Medline

M. Martin-LLahi, M. Guevara, A. Torre, C. Fagundes, T. Restuccia, R. Gilabert.Prognostic importance of the cause of renal failure in patients with cirrhosis.Gastroenterol, 140 (2011), pp. 48-496

P. Giní¨s, P. Angeli, K. Lenz, S. Mí¸ller, K. Moore, R. Moreau, for the European Association for the Study of the Liver, et al.EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis.J Hepatol, 53 (2010), pp. 397-417http://dx.doi.org/10.1016/j.jhep.2010.05.004 | Medline

C. Fagundes, P. Giní¨s.Hepatorenal syndrome: A severe, but treatable, cause of kidney failure in cirrhosis.Am J Kidney Dis, 59 (2012), pp. 874-885http://dx.doi.org/10.1053/j.ajkd.2011.12.032 | Medline

A. Sanyal, T. Boyer, G. Garcia-Tsao, F. Regenstein, L. Rossaro, B. Appenrodt, et al.A prospective, randomized, double blind, placebo-controlled trial of terlipressin for type1 hepatorenal syndrome (HRS).Gastroenterology, 134 (2008), pp. 1360-1368http://dx.doi.org/10.1053/j.gastro.2008.02.014 | Medline

[37]M. Martin-Llahi, M.N. Pepin, G. Guevara, F. Dí­az, A. Torre, A. Monescillo, et al.Terlipressin and albumin vs albumin in patients with cirrhosis and hepatorenal syndrome: A randomized study.Gastroenterology, 134 (2008), pp. 1352-1359http://dx.doi.org/10.1053/j.gastro.2008.02.024 | Medline

[38]L.L. Gluud, K. Christensen, E. Christensen, A. Krag.Systematic review of randomized trials on vasoconstrictor drugs for hepatorenal syndrome.Hepatology, 51 (2010), pp. 576-584http://dx.doi.org/10.1002/hep.23286 | Medline

[39]P. Angeli, P. Giní¨s.Hepatorenal syndrome, MELD score and liver transplantation: An evolving issue with relevant implications for clinical practice.J Hepatol, 57 (2012), pp. 1135-1140http://dx.doi.org/10.1016/j.jhep.2012.06.024 | Medline

[40]R. Bañares, F. Nevens, F.S. Larsen, R. Jalan, A. Albillos, M. Dollinger, et al.Extracorporeal albumin dialysis with the molecular adsorbent recirculating system inacute-on-chronic liver failure: The RELIEF trial.Hepatology, 57 (2013), pp. 1153-1162http://dx.doi.org/10.1002/hep.26185 | Medline

[41]A. Kribben, G. Gerken, S. Haag, S. Herget-Rosenthal, U. Treichel, C. Betz, et al.Effects of fractionated plasma separation and adsorption on survival in patients withacute-on-chronic liver failure.Gastroenterology, 142 (2012), pp. 782-789http://dx.doi.org/10.1053/j.gastro.2011.12.056 | Medline

[42]Hepatic encephalopathy in chronic liver disease: 2014 Practice Guideline by the European Association for the Study of the Liver and the American Association for the Study of Liver Diseases.J Hepatol, 61 (2014), pp. 642-659http://dx.doi.org/10.1016/j.jhep.2014.05.042 | Medline

[43]J. Córdoba, B. Mí­nguez.Hepatic encephalopathy.Semin Liver Dis, 28 (2008), pp. 70-80http://dx.doi.org/10.1055/s-2008-1040322 | Medline

[44]J.S. Bajaj, J. Cordoba, K.D. Mullen, P. Amodio, D.L. Shawcross, R.F. Butterworth, et al.Review article: The design of clinical trials in hepatic encephalopathy—an International Society for Hepatic Encephalopathy and Nitrogen Metabolism (ISHEN) consensus statement.Aliment Pharmacol Ther, 33 (2011), pp. 739-747http://dx.doi.org/10.1111/j.1365-2036.2011.04590.x | Medline

[45]P. Amodio, F. del Piccolo, E. Pettení², D. Mapelli, P. Angeli, R. Iemmolo, et al.Prevalence and prognostic value of quantified electroencephalogram (EEG) alterations in cirrhotic patients.J Hepatol, 35 (2001), pp. 37-45Medline

[46]J. Bustamante, A. Rimola, P.J. Ventura, M. Navasa, I. Cirera, V. Reggiardo, et al.Prognostic significance of hepatic encephalopathy in patients with cirrhosis.J Hepatol, 30 (1999), pp. 890-895Medline

[47]M.D. Leise, J.J. Poterucha, P.S. Kamath, W.R. Kim.Management of hepatic encephalopathy in the hospital.Mayo Clin Proc, 89 (2014), pp. 241-253http://dx.doi.org/10.1016/j.mayocp.2013.11.009 | Medline

[48]J.S. Bajaj, J.B. Wade, D.P. Gibson, D.M. Heuman, L.R. Thacker, R.K. Sterling, et al.The multi-dimensional burden of cirrhosis and hepatic encephalopathy on patients andcaregivers.Am J Gastroenterol, 106 (2011), pp. 1646-1653http://dx.doi.org/10.1038/ajg.2011.157 | Medline

[49]J.S. Bajaj, C.M. Schubert, D.M. Heuman, J.B. Wade, D.P. Gibson, A. Topaz, et al.Persistence of cognitive impairment after resolution of overt hepatic encephalopathy.Gastroenterology, 138 (2010), pp. 2332-2340http://dx.doi.org/10.1053/j.gastro.2010.02.015 | Medline

[50]M. Guevara, M.E. Baccaro, A. Torre, B. Gómez-Ansón, J. Rí­os, F. Torres, et al.Hyponatremia is a risk factor of hepatic encephalopathy in patients with cirrhosis: A prospective study with time-dependent analysis.Am J Gastroenterol, 104 (2009), pp. 1382-1389http://dx.doi.org/10.1038/ajg.2009.293 | Medline

[51]W. Laleman, M. Simon-Talero, G. Maleux, M. Perez, K. Ameloot, G. Soriano, et al.Embolization of large spontaneous portosystemic shunts for refractory hepatic encephalopathy: A multicenter survey on safety and efficacy.Hepatology, 57 (2013), pp. 2448-2457http://dx.doi.org/10.1002/hep.26314 | Medline

[52]H. Grí¸nbaek, S.P. Johnsen, P. Jepsen, M. Gislum, H. Vilstrup, U. Tage-Jensen, et al.Liver cirrhosis, other liver diseases, and risk of hospitalisation for intracerebral haemorrhage: A Danish population-based case-control study.BMC Gastroenterol, 8 (2008), pp. 16http://dx.doi.org/10.1186/1471-230X-8-16 | Medline

Descargas

Publicado

2021-12-04

Cómo citar

Bravo-Coello, J. R., Pacheco-Moreira, V. A., Monar-Goyes, M. C., & Chuncho-Romero, J. C. (2021). Manejo clí­nico y terapéutico en pacientes con cirrosis hepótica. Dominio De Las Ciencias, 7(4), 90–112. https://doi.org/10.23857/dc.v7i4.2412

Número

Vol. 7 Núm. 4 (2021): ESPECIAL DICIEMBRE 2021

Sección

Artí­culos Cientí­ficos

Licencia

Authors retain copyright and guarantee the Journal the right to be the first publication of the work. These are covered by a Creative Commons (CC BY-NC-ND 4.0) license that allows others to share the work with an acknowledgment of the work authorship and the initial publication in this journal.

Artículos más leídos del mismo autor/a